# Renovion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renovion

- Industry: Biotechnology
- Headquarters: Chapel Hill, US
- Website: www.renovion.com
- Total disclosed funding: $8.1M
- Latest round: Series A (Jun 18, 2020)
- Investors on record: 2

## About

Renovion, Inc. is a biotechnology company focused on developing innovative therapies that restore lung health for patients suffering from serious respiratory conditions.Renovion, Inc., based in Chapel Hill, US, was founded in 2013 and specializes in lung health therapies. The company has completed six funding deals, with the most recent being a Series A round on June 18, 2020, where it raised USD 8.1 mn led by WhiteRock Capital Partners. The company's CEO is Dan Copeland.Renovion, Inc. specializes in developing innovative therapies aimed at restoring lung health, particularly for patients suffering from conditions such as lung transplant complications, non-cystic fibrosis bronchiectasis (NCFBE), and chronic bronchitis (CB). Its flagship product, ARINA·1, is designed to enhance mucus clearance in the lungs, addressing significant health challenges faced by patients requiring lung transplantations and those diagnosed with chronic respiratory conditions. The company's products are positioned in various international healthcare markets, focusing on regions where respiratory diseases are prevalent, ensuring access for healthcare providers, clinics, and hospitals that specialize in respiratory care.Renovion operates on a revenue model that includes direct sales to healthcare providers and participation in clinical trials, primarily focusing on its lead product, ARINA·1. Revenue generation is primarily derived from the sale of ARINA·1, as well as potential collaborations with pharmaceutical companies for further development and marketing of new therapies. As the company advances through clinical trials and regulatory approvals, structured pricing plans for ARINA·1 will reflect its value in improving patient quality of life and managing chronic respiratory conditions, positioning Renovion to capitalize on the growing demand for effective lung health solutions.Renovion, Inc. plans to utilize the recent Series A funding of USD 8.1 mn to support the development and launch of new products, including enhancements to ARINA·1. The company aims to expand into new markets, particularly targeting regions in Europe and Asia by the end of 2022. This strategic expansion is aimed at increasing accessibility to its lung health therapies and addressing the rising demand for effective treatments in these regions.

## Funding rounds

- Series A, Jun 18, 2020, $8.1M — WhiteRock Capital Partners
- Series A, Apr 27, 2020 — Texas Halo Fund

## Investors

- Texas Halo Fund (https://capitalatlas.ai/funds/texas-halo-fund) — Series A
- WhiteRock Capital Partners (https://capitalatlas.ai/funds/whiterock-capital-partners) — Series A